Edition:
United Kingdom

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

4.90EUR
11:23am BST
Change (% chg)

€-0.19 (-3.65%)
Prev Close
€5.09
Open
€5.09
Day's High
€5.10
Day's Low
€4.90
Volume
286,355
Avg. Vol
139,253
52-wk High
€16.85
52-wk Low
€4.76

Chart for

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.61
Market Cap(Mil.): €367.11
Shares Outstanding(Mil.): 40.79
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.72 -- --
ROI: -86.39 14.84 14.38
ROE: -332.06 16.34 16.07

BRIEF-AB Science Announces Negative Opinion From CHMP

* REG-AB SCIENCE ANNOUNCES THAT THE CHMP HAS ADOPTED A NEGATIVE OPINION FOR THE MARKETING AUTHORIZATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS

19 Apr 2018

BRIEF-Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size

* REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE

04 Jan 2018

BRIEF-AB Science announces publication of preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments

* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA SHOWING THAT MASITINB IS CAPABLE OF COUNTERACTING RESISTANCE TO ONCOLOGY TREATMENTS

21 Nov 2017

Earnings vs. Estimates